Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
25 juil. 2023 08h47 HE
|
Nexcella, Inc.
LOS ANGELES, July 25, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been...
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
25 juil. 2023 08h42 HE
|
Immix Biopharma, Inc.
LOS ANGELES, July 25, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that updated NXC-201 relapsed/refractory...
Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
10 juil. 2023 09h52 HE
|
Nexcella, Inc.
LOS ANGELES, July 10, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced the completion of its initial CAR-T NXC-201 engineering batch at its U.S....
Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
10 juil. 2023 09h47 HE
|
Immix Biopharma, Inc.
LOS ANGELES, July 10, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced the completion of its initial CAR-T...
Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
26 juin 2023 09h54 HE
|
Nexcella, Inc.
LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies targeting oncology and other...
Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
26 juin 2023 09h49 HE
|
Immix Biopharma, Inc.
LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies...
Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
22 juin 2023 09h58 HE
|
Nexcella, Inc.
Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry, including 7 years as Chief Financial Officer of...
Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
22 juin 2023 09h53 HE
|
Immix Biopharma, Inc.
Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry, including 7 years as Chief Financial Officer of...
Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors
20 juin 2023 09h50 HE
|
Nexcella, Inc.
Mr. Cooper joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical industry, including 5 years as Chief Financial Officer of BioMarin...
Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors
20 juin 2023 09h45 HE
|
Immix Biopharma, Inc.
Mr. Cooper joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical industry, including 5 years as Chief Financial Officer of BioMarin...